N@N

Anika Therapeutics to Webcast Presentation at Canaccord Adams Musculoskeletal Conference

^{Published on 2009-02-19 13:51:01, Last Modified on 2009-02-19 13:51:43 - Market Wire}
 

BEDFORD, Mass.--([ BUSINESS WIRE ])--Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that Charles Sherwood, president and chief executive officer, will be presenting at the Canaccord Adams Musculoskeletal Conference on Tuesday, February 24, 2009 at 10:20 a.m. PT (1:20 p.m. ET). A live audio webcast of the presentation may be accessed via the Internet at: [ http://www.newswire.ca/en/webcast/viewEvent.cgi?eventID=2550240 ]. In addition, the presentation will be available live at the "Investors" section of Anika's website at [ www.anikatherapeutics.com ].

Within the presentation Dr. Sherwood will discuss the current state of the business, including the Company's [ joint health ] product franchise and related U.S. clinical trial for [ MONOVISC™ ], a single-injection treatment for osteoarthritis.

About Anika Therapeutics, Inc.

Headquartered in Bedford, Mass., [ Anika Therapeutics, Inc ]. develops, manufactures and commercializes therapeutic products for tissue protection, healing and repair. These products are based on [ hyaluronic acid (HA) ], a naturally occurring, biocompatible polymer found throughout the body. Anika's products include [ ORTHOVISC ]^®, a treatment for osteoarthritis of the knee available internationally and marketed in the U.S. by DePuy Mitek; [ HYVISC ]^{[ ® ]}, a treatment for equine osteoarthritis marketed in the U.S. by Boehringer Ingelheim Vetmedica, Inc.; the [ ELEVESS™ ] family of aesthetic dermatology products for facial wrinkles, scar remediation and lip augmentation; [ AMVISC ]^{[ ® ]}[ , AMVISC ]^{[ ® ]}[ Plus, STAARVISC™-II and Shellgel™ ] injectable viscoelastic HA products for ophthalmic surgery; [ INCERT ]^{[ ® ]}, an HA-based anti-adhesive for surgical applications; [ ORTHOVISC ]^{[ ® ]}[ mini ] a treatment for osteoarthritis targeting small joints and available in Europe; [ MONOVISC™ ] a single-injection osteoarthritis product based on our proprietary cross-linking technology and also available in Europe; and next generation products for joint health and aesthetic dermatology based on the Company's proprietary, chemically modified HA.